Table 2.

In vitro inhibitory effect of compounds 3–23 on the proliferation of the human-derived tumor cell lines: T24 (bladder), DU-145 (prostate) and MCF7 (breast) and the non-tumor fibroblasts (Balb/3T3).

					EC50 ± SEM a (μM)
N°	R1	R2	R3	R4	T24	DU-145	MCF-7	BALB/3T3	MSI b
3	H	H	H	H	186.4 ± 20.4	205.0 ± 21.5	189.8 ± 19.2	38.5 ± 5.5	0.20
4	Me	H	H	H	172.5 ± 13.2	172.5 ± 19.7	180.7 ± 15.8	183.9 ± 17.6	1.06
5	H	Me	H	H	202.3 ± 15.9	186.2 ± 17.8	225.7 ± 24.2	100.3 ± 9.5	0.49
6	H	H	H	Me	208.9 ± 19.5	100.8 ± 9.5	142.1 ± 15.3	78.3 ± 6.4	0.57
7	H	OMe	H	H	209.7 ± 20.5	166.1 ± 15.8	154.4 ± 12.3	117.6 ± 19.5	0.68
8	H	H	OMe	H	168.1 ± 12.2	170.2 ± 15.5	190.7 ± 17.5	85.2 ± 9.7	0.49
9	OMe	H	H	OMe	149.7 ± 18.4	130.3 ± 12.5	164.5 ± 13.8	43.7 ± 7.6	0.29
10	H	H	OMe	OMe	147.4 ± 19.2	140.0 ± 13.6	182.9 ± 17.7	35.4 ± 4.7	0.23
11	H	OMe	OH	H	154.5 ± 14.5	167.5 ± 15.9	176.7 ± 19.4	78.0 ± 9.3	0.47
12	H	OMe	OMe	OMe	3.6 ± 1.4	1.2 ± 0.6	53.6 ± 6.7	1.5 ± 0.4	0.57
13	H	OMe	OH	OMe	>350	112.8 ± 10.7	>350	19.1 ± 3.1	-
14	Me	H	H	H	143.3 ± 9.5	143.8 ± 17.7	152.3 ± 14.5	225.5 ± 25.4	1.54
15	H	Me	H	H	136.8 ± 11.7	147.4 ± 15.9	144.9 ± 12.7	142.4 ± 13.9	0.99
16	H	H	Me	H	134.6 ± 12.8	158.3 ± 13.7	133.8 ± 14.9	138.9 ± 15.2	0.98
17	H	OMe	H	H	133.3 ± 12.4	139.4 ± 11.3	127.9 ± 13.6	109.1 ± 11.1	0.82
18	H	H	OMe	H	126.8 ± 10.6	77.5 ± 6.5	124.9 ± 10.2	107.0 ± 12.3	1.03
19	OMe	H	H	OMe	129.8 ± 10.1	128.7 ± 17.2	>310	100.3 ± 8.9	0.77
20	H	H	OMe	OMe	46.8 ± 5.1	61.8 ± 5.6	12.2 ± 3.8	2.8 ± 0.6	0.11
21	H	H	OH	OMe	86.6 ± 9.6	89.0 ± 7.3	15.7 ± 4.6	15.7 ± 3.9	0.45
22	H	OMe	OMe	OMe	13.5 ±1.9	5.9 ± 0.8	20.2 ± 4.5	25.1 ± 3.9	2.45
23	H	OMe	OH	OMe	112.0 ± 9.3	113.5 ± 9.5	130.2 ± 14.8	99.6 ± 7.5	0.84
DOXc	-	-	-	-	0.65 ± 0.07	0.42 ± 0.03	0.33 ± 0.05	0.19 ± 0.01	0.44
MITd	-	-	-	-	42.2 ± 5.8	14.3 ± 2.6	16.8 ± 2.9	27.3 ± 3.3	1.39

^a Data represent EC₅₀ mean values ± SEM of at least three different experiments; ^b MSI: Mean Selective Index = EC₅₀ values fibroblasts/EC₅₀ values tumor cells; ^c DOX: doxorubicin; ^d MIT: mitomycin C.